Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

The so-called amyloid hypothesis, that the accumulation and deposition of oligomeric or
fibrillar amyloid β (Aβ) peptide is the primary cause of Alzheimer's disease (AD), has been …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer's disease (AD). Recently, we showed that abnormal levels of Aβ42 in …

See Mander et al.(doi: 10.1093/awx174) for a scientific commentary on this article. Sleep
deprivation increases amyloid-β, suggesting that chronically disrupted sleep may promote …

Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Introduction We examined and compared plasma phospho-tau181 (pTau181) and total
tau:(1) across the Alzheimer's disease (AD) clinical spectrum;(2) in relation to brain amyloid …

Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Since its discovery in 1984, the beta amyloid peptide has treaded the boards of
neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade …